One such commonly used medication for dermatologic and rheumatologic inflammatory conditions is hydroxychloroquine (Plaquenil), a chloroquine derivative. It is used to treat many diseases including malaria, rheumatoid arthritis and systemic lupus erythematosus. Plaquenil and epidural anesthesia Can plaquenil cause w Sjogrens plaquenil available Hydroxychloroquine retinopathy The results of the tests may be assessed after you. have left the clinic. When they have been assessed a report will be sent to you, your GP and/or the hospital doctor who prescribed hydroxychloroquine. No signs of retinopathy. If the tests do not show signs of retinopathy, you will be invited back for re-screening in one year. All the tests will be assessed by an ophthalmologist hospital eye doctor after you have left the clinic. A report will be sent to you, your GP and/or the hospital doctor who prescribed hydroxychloroquine. No signs of retinopathy. If all the tests show a normal retina then there are no signs of retinopathy. Currently, one of the primary functional screening tests recommended for the evaluation of Plaquenil retinal toxicity is 10-2 white stimulus automated visual fields; however, research shows Asian patients benefited from 24-2 or 30-2 visual fields, given that toxicity often manifests changes beyond the macula in these patients. 9 Because spectral-domain optical coherence tomography SD-OCT is readily accessible and able to detect early structural damage prior to clinical funduscopic findings. It is imperative that patients and physicians are aware of and watch for this drug’s ocular side effects. Retinal toxicity from hydroxychloroquine is rare, but even if the medication is discontinued, vision loss may be irreversible and may continue to progress. Test for plaquenil retinopathy Hydroxychloroquine screening, Eye screening for patients taking hydroxychloroquine Plaquenil Hydroxychloroquine eye testNursing interventions for hydroxychloroquinePlaquenil sun pharmaceuticals 347 The American Academy of Ophthalmology recommendations for screening of chloroquine CQ and hydroxychloroquine HCQ retinopathy were published in 2002, but improved screening tools and new knowledge about the prevalence of toxicity have appeared in the ensuing years. Revised Recommendations on Screening for Chloroquine and.. How to Succeed in Plaquenil Screenings. Plaquenil Toxicity - Symptoms, Treatment, Risk Factors.. Find an Ophthalmologist. Abstract Background The American Academy of Ophthalmology recommendations on screening for chloroquine CQ and hydroxychloroquine HCQ retinopathy are revised in light of new information about the prevalence of toxicity, risk factors, fundus distribution, and effectiveness of screening tools. Here is a look at the 2011 testing guidelines for patients on Plaquenil guidelines. Diana L. Shechtman, O. D. and Paul M. Karpecki, O. D. A 45-year-old black female presented with no ocular or visual complaints. Her ocular history was unremarkable. However, her medical history was significant for a recent diagnosis of lupus. Plaquenil, hydroxychloroquine HCQ, is an anti-malarial medication that has been proven to be useful in the treatment of patients with rheumatoid arthritis RA, systemic lupus erythematosus SLE and other inflammatory and autoimmune diseases. In Sjögren’s, Plaquenil is used to treat many symptoms of Sjögren’s including fatigue, joint.